FLSM
TRVI icon

Frazier Life Sciences Management’s Trevi Therapeutics TRVI Stock Holding History

Frazier Life Sciences Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185M Sell
9,939,447
-100
-0% -$1.45K 4.04% 6
2026
Q1 		$119M Sell
9,939,547
-319,862
-3% -$3.58M 3.05% 10
2025
Q4 		$128M Hold
10,259,409
– – 3.45% 8
2025
Q3 		$93.9M Hold
10,259,409
– – 2.81% 11
2025
Q2 		$56.1M Hold
10,259,409
– – 2.24% 11
2025
Q1 		$64.5M Sell
10,259,409
-405,365
-4% -$1.93M 2.95% 9
2024
Q4 		$43.9M Buy
10,664,774
+3,283,684
+44% +$10.5M 1.82% 14
2024
Q3 		$24.7M Hold
7,381,090
– – 0.99% 25
2024
Q2 		$22M Hold
7,381,090
– – 1.03% 26
2024
Q1 		$25.5M Hold
7,381,090
– – 1.07% 27
2023
Q4 		$9.89M Buy
7,381,090
+500,000
+7% +$757K 0.53% 42
2023
Q3 		$15M Hold
6,881,090
– – 1% 24
2023
Q2 		$16.4M Buy
6,881,090
+217,500
+3% +$548K 0.98% 28
2023
Q1 		$12.3M Hold
6,663,590
– – 0.89% 26
2022
Q4 		$12.9M Buy
6,663,590
+1,260,000
+23% +$2.48M 0.8% 25
2022
Q3 		$8.32M Buy
5,403,590
+4,231,963
+361% +$13.9M 0.64% 33
2022
Q2 		$3.29M Buy
+1,171,627
New +$2.88M 0.31% 33

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Frazier Life Sciences Management's TRVI Position: Q2 2026 in Review

Frazier Life Sciences Management reduced its Trevi Therapeutics (TRVI) stake by 0% in Q2 2026, selling an estimated $1.45K and leaving 9,939,447 shares worth $185M. The position accounts for 4.04% of the portfolio, ranked #6.

Frazier Life Sciences Management first reported a position in TRVI in Q2 2022 and has held it in 17 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Frazier Life Sciences Management held 9,939,447 shares of Trevi Therapeutics worth $185M as of Q2 2026.
  • Frazier Life Sciences Management sold 100 Trevi Therapeutics shares in Q2 2026, an estimated $1.45K.
  • Trevi Therapeutics made up 4.04% of Frazier Life Sciences Management's portfolio in Q2 2026, its #6 holding.
  • Frazier Life Sciences Management first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.